跳转至内容
Merck
所有图片(1)

主要文件

565740

Sigma-Aldrich

α-淀粉样蛋白前体蛋白质调节剂

≥95% (HPLC), solid, PKC activator, Calbiochem®

别名:

α-淀粉样蛋白前体蛋白质调节剂

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C27H30F3N3O3
分子量:
501.54
MDL號碼:
分類程式碼代碼:
12352202
NACRES:
NA.77

产品名称

α-淀粉样蛋白前体蛋白质调节剂, A cell-permeable benzolactam derived PKC activator (Ki = 11.9 nM for PKCα) that efficiently enhances non-amyloidogenic α-processing of amyloid precursor protein (APP) even at 100 nM in human fibroblast AG06848.

品質等級

化驗

≥95% (HPLC)

形狀

solid

製造商/商標名

Calbiochem®

儲存條件

OK to freeze
protect from light

顏色

orange

溶解度

methanol: 1 mg/mL
DMSO: 50 mg/mL

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

FC(F)(F)c1ccc(cc1)\C=C\C=C\C(=O)Nc2cc3c(cc2)N([C@H](C(=O)N[C@@H](C3)CO)C(C)C)C

InChI

1S/C27H30F3N3O3/c1-17(2)25-26(36)32-22(16-34)15-19-14-21(12-13-23(19)33(25)3)31-24(35)7-5-4-6-18-8-10-20(11-9-18)27(28,29)30/h4-14,17,22,25,34H,15-16H2,1-3H3,(H,31,35)(H,32,36)/b6-4+,7-5+/t22-,25-/m0/s1

InChI 密鑰

WOLVEMPZUIFSII-IHHOKICGSA-N

一般說明

一种细胞渗透性PKC激活剂(PKCα的Ki=11.9 nM),有效增强淀粉样前体蛋白(APP)的非淀粉样α加工,但缺乏任何促肿瘤活性。
一种细胞渗透性苯并内酰胺衍生的PKC激活剂(PKCα的Ki=11.9 nM),即使在100 nM时,也可有效增强人成纤维细胞AG06848中淀粉样前体蛋白(APP)的非淀粉样α-加工。显示肿瘤促进活性显着丧失。

生化/生理作用

主要靶标
PKC
产物不与ATP竞争。
可逆:否
细胞可渗透性:是
靶标Ki:对于活化PKC为11.9 nMα

包裝

用惰性气体包装

警告

毒性:标准处理(A)

重構

复溶后,等分并冷冻保存(-20°C)。贮备溶液在-20°C下可稳定保存至多6个月。

其他說明

Kozikowski, A.P., et al. 2003.J. Med. Chem.46, 364.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Yan Fung Wong et al.
Nature cell biology (2023-01-24)
Cell proliferation is fundamental for almost all stages of development and differentiation that require an increase in cell number. Although cell cycle phase has been associated with differentiation, the actual process of proliferation has not been considered as having a
Ana-Maria Cujba et al.
Cell reports, 38(9), 110425-110425 (2022-03-03)
The HNF1αp291fsinsC truncation is the most common mutation associated with maturity-onset diabetes of the young 3 (MODY3). Although shown to impair HNF1α signaling, the mechanism by which HNF1αp291fsinsC causes MODY3 is not fully understood. Here we use MODY3 patient and
Sisi Feng et al.
Cell reports, 33(10), 108455-108455 (2020-12-10)
The ever-increasing therapeutic and pharmaceutical demand for liver cells calls for systems that enable mass production of hepatic cells. Here we describe a large-scale suspension system that uses human endoderm stem cells (hEnSCs) as precursors to generate functional and transplantable

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门